Breaking News, Financial News

Financial Report: PDL BioPharma

Royalty revenues up 19% in the quarter

PDL BioPharma

1Q Revenues: $91.8 million (+19%)

1Q Earnings: $53.5 million (+33%)

Comments: Royalty revenues were up 19% driven by increased royalties from Avastin, Herceptin, Lucentis, Tysabri, and Actemra.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters